<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ajpcell.physiology.org">
<title>AJP: Cell Physiology current issue</title>
<link>http://ajpcell.physiology.org</link>
<description>AJP: Cell Physiology RSS feed -- current issue</description>
<prism:eIssn>1522-1563</prism:eIssn>
<prism:coverDisplayDate>Nov  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>AJP: Cell Physiology</prism:publicationName>
<prism:issn>0363-6143</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/full/297/5/C1059?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1062?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1071?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1082?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/1091?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1103?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1113?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/1124?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1133?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1146?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1157?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1168?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1178?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1188?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1200?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1211?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1220?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1228?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1236?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1249?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1263?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1275?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1284?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1294?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1307?rss=1" />
  <rdf:li rdf:resource="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1318?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ajpcell.physiology.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ajpcell.physiology.org/icons/banner/title.gif">
<title>AJP: Cell Physiology</title>
<url>http://ajpcell.physiology.org/icons/banner/title.gif</url>
<link>http://ajpcell.physiology.org</link>
</image>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/full/297/5/C1059?rss=1">
<title><![CDATA[Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells"]]></title>
<link>http://ajpcell.physiology.org/cgi/content/full/297/5/C1059?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Kimura, K., Eguchi, S.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00399.2009</dc:identifier>
<dc:title><![CDATA[Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Focus on "Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells"]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1061</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1059</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1062?rss=1">
<title><![CDATA[Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1062?rss=1</link>
<description><![CDATA[
<p>Angiotensin II (ANG II) is a major regulator of blood pressure that essentially acts through activation of ANG II type 1 receptor (AT1R) of vascular smooth muscle cells (VSMC). AT1R activates numerous intracellular signaling pathways, including the small G protein RhoA known to control several VSMC functions. Nevertheless, the mechanisms leading to RhoA activation by AT1R are unknown. RhoA activation can result from activation of RhoA exchange factor and/or inhibition of Rho GTPase-activating protein (GAP). Here we hypothesize that a RhoGAP could participate to RhoA activation induced by ANG II in rat aortic VSMC. The knockdown of the RhoGAP p190A by small interfering RNA (siRNA) abolishes the activation of RhoA-Rho kinase pathway induced after 5 min of ANG II (0.1 &micro;M) stimulation in rat aortic VSMC. We then show that AT1R activation induces p190A dephosphorylation and inactivation. In addition, expression of catalytically inactive or phosphoresistant p190A mutants increases the basal activity of RhoA-Rho kinase pathway, whereas phosphomimetic mutant inhibits early RhoA activation by ANG II. Using siRNA and mutant overexpression, we then demonstrate that the tyrosine phosphatase SHP2 is necessary for <I>1</I>) maintaining p190A basally phosphorylated and activated by the tyrosine kinase c-Abl, and <I>2</I>) inducing p190A dephosphorylation and RhoA activation in response to AT1R activation. Our work then defines p190A as a new mediator of RhoA activation by ANG II in VSMC.</p>
]]></description>
<dc:creator><![CDATA[Bregeon, J., Loirand, G., Pacaud, P., Rolli-Derkinderen, M.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00174.2009</dc:identifier>
<dc:title><![CDATA[Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1070</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1062</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1071?rss=1">
<title><![CDATA[Loss of the apical V-ATPase a-subunit VHA-6 prevents acidification of the intestinal lumen during a rhythmic behavior in C. elegans]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1071?rss=1</link>
<description><![CDATA[
<p>In <I>Caenorhabditis elegans</I>, oscillations of intestinal pH contribute to the rhythmic defecation behavior, but the acid-base transport mechanisms that facilitate proton movement are not well understood. Here, we demonstrate that VHA-6, an intestine-specific a-subunit of the H<sup>+</sup>-K<sup>+</sup>-ATPase complex (V-ATPase), resides in the apical membrane of the intestinal epithelial cells and is required for luminal acidification. Disruption of the <I>vha-6</I> gene led to early developmental arrest; the arrest phenotype could be complemented by expression of a fluorescently labeled <I>vha-6</I> transgene. To study the contribution of <I>vha-6</I> to pH homeostasis in larval worms, we used a partial reduction of function through postembryonic single-generation RNA interference. We demonstrate that the inability to fully acidify the intestinal lumen coincides with a defect in pH recovery of the intestinal epithelial cells, suggesting that VHA-6 is essential for proton pumping following defecation. Moreover, intestinal dipeptide accumulation and fat storage are compromised by the loss of VHA-6, suggesting that luminal acidification promotes nutrient uptake in worms, as well as in mammals. Since acidified intracellular vesicles and autofluorescent storage granules are indistinguishable between the <I>vha-6</I> mutant and controls, it is likely that the nutrient-restricted phenotype is due to a loss of plasma membrane V-ATPase activity specifically. These data establish a simple genetic model for proton pump-driven acidification. Since defecation occurs at 45-s intervals in worms, this model represents an opportunity to study acute regulation of V-ATPase activity on a short time scale and may be useful in the study of alternative treatments for acid-peptic disorders.</p>
]]></description>
<dc:creator><![CDATA[Allman, E., Johnson, D., Nehrke, K.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00284.2009</dc:identifier>
<dc:title><![CDATA[Loss of the apical V-ATPase a-subunit VHA-6 prevents acidification of the intestinal lumen during a rhythmic behavior in C. elegans]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1081</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1071</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1082?rss=1">
<title><![CDATA[An environmental sensor, TRPV4 is a novel regulator of intracellular Ca2+ in human synoviocytes]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1082?rss=1</link>
<description><![CDATA[
<p>The activation of a vanilloid type 4 transient receptor potential channel (TRPV4) has an obligatory role in regulation of intracellular Ca<sup>2+</sup> (Ca<sup>2+</sup><SUB>i</SUB>) in several types of cells including vascular and sensory organs. In this study, we provide evidence that TRPV4 is a functional regulator of Ca<sup>2+</sup><SUB>i</SUB> in human synoviocytes. Although significant expression of TRPV4 in synoviocytes from patients with (RA) and without (CTR) rheumatoid arthritis was detected at mRNA and protein level, those in the human fibroblast-like synoviocyte line MH7A were rather lower. Consistently, the selective TRPV4 agonist 4-phorbol 12,13-didecanoate (4PDD) effectively elevated Ca<sup>2+</sup><SUB>i</SUB> in the RA and CTR cells, which was abolished by the removal of external Ca<sup>2+</sup>. Moreover, the elevation was inhibited by ruthenium red, a blocker of TRPVs. In MH7A cells transfected with human TRPV4 (MH7A-V4), 4PDD elevated the Ca<sup>2+</sup><SUB>i</SUB> in a similar manner to those in the RA and CTR cells. Electrophysiological analysis also revealed that 4PDD activated nonselective cationic currents in RA cells. Application of 227 mosM solution to the RA and MH7A-V4 cells elevated their Ca<sup>2+</sup><SUB>i</SUB>, but this does not occur when it was applied to MH7A cells. Treatment of RA but not MH7A cells with 4PDD for 24 h reduced their production of IL-8. These results suggest that an environmental sensor, TRPV4, is a novel regulator of intracellular Ca<sup>2+</sup> in human synoviocytes.</p>
]]></description>
<dc:creator><![CDATA[Itoh, Y., Hatano, N., Hayashi, H., Onozaki, K., Miyazawa, K., Muraki, K.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00204.2009</dc:identifier>
<dc:title><![CDATA[An environmental sensor, TRPV4 is a novel regulator of intracellular Ca2+ in human synoviocytes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1090</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1082</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/1091?rss=1">
<title><![CDATA[Bicarbonate homeostasis in excitable tissues: role of AE3 Cl-/HCOFormula exchanger and carbonic anhydrase XIV interaction]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/1091?rss=1</link>
<description><![CDATA[
<p>Bicarbonate transport and metabolism are key elements of normal cellular function. Two alternate transcripts of anion exchanger 3 (AE3), full-length (AE3fl) and cardiac (AE3c), are expressed in central nervous system (CNS), where AE3 catalyzes electroneutral Cl<sup>&ndash;</sup>/HCO<f><SUB>3</SUB><sup>&ndash;</sup></f> exchange across the plasma membrane of neuronal and glial cells of CNS. Anion exchanger isoforms, AE3fl and AE3c, associate with the carbonic anhydrases (CA) CAII and CAIV, forming a HCO<f><SUB>3</SUB><sup>&ndash;</sup></f> transport metabolon, to maximize HCO<f><SUB>3</SUB><sup>&ndash;</sup></f> flux across the plasma membrane. CAXIV, with catalytic domain anchored to the extracellular surface, is also expressed in CNS. Here physical association of AE3 and CAXIV was examined by coimmunoprecipitation experiments, using mouse brain and retinal lysates. CAXIV immunoprecipitated with anti-AE3 antibody, and both AE3 isoforms were immunoprecipitated using anti-CAXIV antibody, indicating CAXIV and AE3 interaction in the CNS. Confocal images revealed colocalization of CAXIV and AE3 in M&uuml;ller and horizontal cells, in the mouse retina. Cl<sup>&ndash;</sup>/HCO<f><SUB>3</SUB><sup>&ndash;</sup></f> exchange activity of AE3fl was investigated in transiently transfected human embryonic kidney 293 cells, using intracellular fluorescence measurements of BCECF, to monitor intracellular pH. CAXIV increased the rate of AE3fl-mediated HCO<f><SUB>3</SUB><sup>&ndash;</sup></f> transport by up to 120%, which was suppressed by the CA inhibitor acetazolamide. Association of AE3 and CAXIV may represent a mechanism to enhance disposal of waste CO<SUB>2</SUB> and to balance pH in excitable tissues.</p>
]]></description>
<dc:creator><![CDATA[Casey, J. R., Sly, W. S., Shah, G. N., Alvarez, B. V.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00177.2009</dc:identifier>
<dc:title><![CDATA[Bicarbonate homeostasis in excitable tissues: role of AE3 Cl-/HCOFormula exchanger and carbonic anhydrase XIV interaction]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>1102</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1091</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1103?rss=1">
<title><![CDATA[Orai1, a critical component of store-operated Ca2+ entry, is functionally associated with Na+/Ca2+ exchanger and plasma membrane Ca2+ pump in proliferating human arterial myocytes]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1103?rss=1</link>
<description><![CDATA[
<p>Ca<sup>2+</sup> entry through store-operated channels (SOCs) in the plasma membrane plays an important role in regulation of vascular smooth muscle contraction, tone, and cell proliferation. The C-type transient receptor potential (TRPC) channels have been proposed as major candidates for SOCs in vascular smooth muscle. Recently, two families of transmembrane proteins, Orai [also known as Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channel modulator (CRACM)] and stromal interacting molecule 1 (STIM1), were shown to be essential for the activation of SOCs mainly in nonexcitable cells. Here, using small interfering RNA, we show that Orai1 plays an essential role in activating store-operated Ca<sup>2+</sup> entry (SOCE) in primary cultured proliferating human aortic smooth muscle cells (hASMCs), whereas Orai2 and Orai3 do not contribute to SOCE. Knockdown of Orai1 protein expression significantly attenuated SOCE. Moreover, inhibition of Orai1 downregulated expression of Na<sup>+</sup>/Ca<sup>2+</sup> exchanger type 1 (NCX1) and plasma membrane Ca<sup>2+</sup> pump isoform 1 (PMCA1). The rate of cytosolic free Ca<sup>2+</sup> concentration decay after Ca<sup>2+</sup> transients in Ca<sup>2+</sup>-free medium was also greatly decreased under these conditions. This reduction of Ca<sup>2+</sup> extrusion, presumably via NCX1 and PMCA1, may be a compensation for the reduced SOCE. Immunocytochemical observations indicate that Orai1 and NCX1 are clustered in plasma membrane microdomains. Cell proliferation was attenuated in hASMCs with disrupted Orai1 expression and reduced SOCE. Thus Orai1 appears to be a critical component of SOCE in proliferating vascular smooth muscle cells, and may therefore be a key player during vascular growth and remodeling.</p>
]]></description>
<dc:creator><![CDATA[Baryshnikov, S. G., Pulina, M. V., Zulian, A., Linde, C. I., Golovina, V. A.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00283.2009</dc:identifier>
<dc:title><![CDATA[Orai1, a critical component of store-operated Ca2+ entry, is functionally associated with Na+/Ca2+ exchanger and plasma membrane Ca2+ pump in proliferating human arterial myocytes]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1112</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1103</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1113?rss=1">
<title><![CDATA[Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1113?rss=1</link>
<description><![CDATA[
<p>Dystroglycan is a widely expressed adhesion complex that anchors cells to the basement membrane and is involved in embryonic development and differentiation. Dystroglycan expression is frequently reduced in human dystrophies and malignancies, and its molecular functions are not completely understood. Several posttranslational mechanisms have been identified that regulate dystroglycan expression and/or function, while little is known about how expression of the corresponding <I>Dag1</I> gene is regulated. This study aimed to clone the <I>Dag1</I> gene promoter and to characterize its regulatory elements. Analysis of the mouse <I>Dag1</I> gene 5'-flanking region revealed a TATA and CAAT box-lacking promoter including a GC-rich region. Transfection studies with serially deleted promoter constructs allowed us to identify a minimal promoter region containing three Specificity protein 1 (Sp1) sites and an E-box. Sp1 binding was confirmed by chromatin immunoprecipitation assay, and Sp1 downregulation reduced dystroglycan expression in muscle cells. Treatment with 5-aza-2'-deoxycytidine and/or the histone deacetylase inhibitor trichostatin A increased <I>Dag1</I> mRNA expression levels in myoblasts, and methylation decreased promoter activity in vitro. Furthermore, <I>Dag1</I> gene promoter methylation was reduced while its expression increased during differentiation of C<SUB>2</SUB>C<SUB>12</SUB> myoblast cells in myotubes. In conclusion, for the first time we have characterized the activity of the mouse <I>Dag1</I> gene promoter, confirming a complex regulation by Sp1 transcription factor, DNA methylation, and histone acetylation, which might be relevant for a better understanding of the physiopathology of the dystroglycan complex.</p>
]]></description>
<dc:creator><![CDATA[Rettino, A., Rafanelli, F., Genovese, G., Goracci, M., Cifarelli, R. A., Cittadini, A., Sgambato, A.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00189.2009</dc:identifier>
<dc:title><![CDATA[Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1123</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1113</prism:startingPage>
<prism:section>MUSCLE CELL BIOLOGY AND CELL MOTILITY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/1124?rss=1">
<title><![CDATA[Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/1124?rss=1</link>
<description><![CDATA[
<p>Myostatin is a highly conserved negative regulator of skeletal muscle growth. Loss of functional myostatin in cattle, mice, sheep, dogs, and humans results in increased muscle mass. The molecular mechanisms responsible for this increase in muscle growth are not fully understood. Previously, we have reported that phenylephrine-induced cardiac muscle growth and Akt activation are enhanced in myostatin knockout mice compared with controls. Here we report that skeletal muscle from myostatin knockout mice show increased Akt protein expression and overall activity at baseline secondary to an increase in Akt mRNA. We examined the functional role of myostatin modulation of Akt in C2C12 myotubes, a well-established in vitro model of skeletal muscle hypertrophy. Adenoviral overexpression of myostatin attenuated the insulin-like growth factor-I (IGF-I)-mediated increase in myotube diameter, as well as IGF-I-stimulated Akt phosphorylation. Inhibition of myostatin by overexpression of the NH<SUB>2</SUB>-terminal portion of myostatin was sufficient to increase myotube diameter and Akt phosphorylation. Coexpression of myostatin and constitutively active Akt (myr-Akt) restored the increase in myotube diameter. Conversely, expression of dominant negative Akt (dn-Akt) with the inhibitory myostatin propeptide blocked the increase in myotube diameter. Of note, ribosomal protein S6 phosphorylation and atrogin-1/muscle atrophy F box mRNA were increased in skeletal muscle from myostain knockout mice. Together, these data suggest myostatin regulates muscle growth at least in part through regulation of Akt.</p>
]]></description>
<dc:creator><![CDATA[Morissette, M. R., Cook, S. A., Buranasombati, C., Rosenberg, M. A., Rosenzweig, A.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00043.2009</dc:identifier>
<dc:title><![CDATA[Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>1132</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>1124</prism:startingPage>
<prism:section>MUSCLE CELL BIOLOGY AND CELL MOTILITY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1133?rss=1">
<title><![CDATA[Negative modulation of inositol 1,4,5-trisphosphate type 1 receptor expression prevents dystrophin-deficient muscle cells death]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1133?rss=1</link>
<description><![CDATA[
<p>Evidence for a modulatory effect of cyclosporin A (CsA) on calcium signaling and cell survival in dystrophin-deficient cells is presented. Our previous works strongly supported the hypothesis of an overactivation of Ca<sup>2+</sup> release via inositol 1,4,5-trisphosphate (IP3) receptors (IP3R) in dystrophin-deficient cells, both during membrane depolarization and at rest, through spontaneous Ca<sup>2+</sup> release events. Forced expression of mini-dystrophin in these cells contributed, during stimulation and in resting condition, to the recovery of a controlled calcium homeostasis. In the present work, we demonstrate that CsA exposure displayed a dual-modulator effect on calcium signaling in dystrophin-deficient cells. Short-time incubation induced a decrease of IP3-dependent calcium release, leading to patterns of release similar to those observed in myotubes expressing mini-dystrophin, whereas long-time incubation reduced the expression of the type I of IP3 receptors (IP3R-1) RNA levels. Moreover, both IP3R-1 knockdown and blockade through 2-aminoethoxydiphenyle borate or CsA induced improved survival of dystrophin-deficient myotubes, demonstrating the cell death dependence on the IP3-dependent calcium signaling as well as the protective effect of CsA. Inhibition of the IP3 pathway could be a very interesting approach for reducing the natural cell death of dystrophin-deficient cells in development.</p>
]]></description>
<dc:creator><![CDATA[Mondin, L., Balghi, H., Constantin, B., Cognard, C., Sebille, S.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00048.2009</dc:identifier>
<dc:title><![CDATA[Negative modulation of inositol 1,4,5-trisphosphate type 1 receptor expression prevents dystrophin-deficient muscle cells death]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1145</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1133</prism:startingPage>
<prism:section>MUSCLE CELL BIOLOGY AND CELL MOTILITY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1146?rss=1">
<title><![CDATA[Retinoic acid-induced nNOS expression depends on a novel PI3K/Akt/DAX1 pathway in human TGW-nu-I neuroblastoma cells]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1146?rss=1</link>
<description><![CDATA[
<p>Neuronal nitric oxide synthase (nNOS)-derived nitric oxide (NO) acts as a neurotransmitter and intracellular signaling molecule in the central and peripheral nervous system. NO regulates multiple processes like neuronal development, plasticity, and differentiation and is a mediator of neurotoxicity. The <I>nNOS</I> gene is highly complex with 12 alternative first exons, exon 1a&ndash;1l, transcribed from distinct promoters, leading to nNOS variants with different 5'-untranslated regions. Transcriptional control of the <I>nNOS</I> gene is not understood in detail. To investigate regulation of <I>nNOS</I> gene expression by retinoic acid (RA), we used the human neuroblastoma cell line TGW-nu-I as a model system. We show that RA induces <I>nNOS</I> transcription in a protein synthesis-dependent fashion. We identify the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway and the atypical orphan nuclear receptor DAX1 (NR0B1) as critical mediators involved in RA-induced <I>nNOS</I> gene transcription. RA treatment increases DAX1 expression via PI3K/Akt signaling. Upregulation of DAX1 expression in turn induces nNOS transcription in response to RA. These results identify nNOS as a target gene of a novel RA/PI3K/Akt/DAX1-dependent pathway in human neuroblastoma cells and stress the functional importance of the transcriptional regulator DAX1 for nNOS gene expression in response to RA treatment.</p>
]]></description>
<dc:creator><![CDATA[Nagl, F., Schonhofer, K., Seidler, B., Mages, J., Allescher, H.-D., Schmid, R. M., Schneider, G., Saur, D.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:44 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00034.2009</dc:identifier>
<dc:title><![CDATA[Retinoic acid-induced nNOS expression depends on a novel PI3K/Akt/DAX1 pathway in human TGW-nu-I neuroblastoma cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1156</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1146</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1157?rss=1">
<title><![CDATA[The C type natriuretic peptide receptor tethers AHNAK1 at the plasma membrane to potentiate arachidonic acid-induced calcium mobilization]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1157?rss=1</link>
<description><![CDATA[
<p>Arachidonic acid (AA) liberated from membrane phospholipids is known to activate phospholipase C 1 (PLC1) concurrently with AHNAK in nonneuronal cells. The recruitment of AHNAK from the nucleus is required for it to activate PLC1 at the plasma membrane. Here, we identify the C-type natriuretic peptide receptor (NPR-C), an atypical G protein-coupled receptor, as a protein binding partner for AHNAK1 in various cell types. Mass spectrometry and MASCOT analysis of excised bands from NPR-C immunoprecipitation studies revealed multiple signature peptides corresponding to AHNAK1. Glutathione <I>S</I>-transferase (GST) pulldown assays using GST- AHNAK1 fusion proteins corresponding to each of the distinct domains of AHNAK1 showed the C1 domain of AHNAK1 associates with NPR-C. The role of NPR-C in mediating AA-dependent AHNAK1 calcium signaling was explored in various cell types, including 3T3-L1 preadipocytes during the early stages of differentiation. Sucrose density gradient centrifugation studies showed AHNAK1 resides in the nucleus, cytoplasm, and at the plasma membrane, but small interfering RNA (siRNA)-mediated knockdown of NPR-C resulted in AHNAK1 accumulation in the nucleus. Overexpression of a portion of AHNAK1 resulted in augmentation of intracellular calcium mobilization, whereas siRNA-mediated knockdown of NPR-C or AHNAK1 protein resulted in attenuation of intracellular calcium mobilization in response to phorbol 12-myristate 13-acetate. We characterize the novel association between AHNAK1 and NPR-C and provide evidence that this association potentiates the AA-induced mobilization of intracellular calcium. We address the role of intracellular calcium in the various cell types that AHNAK1 and NPR-C were found to associate.</p>
]]></description>
<dc:creator><![CDATA[Alli, A. A., Gower, W. R.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00219.2009</dc:identifier>
<dc:title><![CDATA[The C type natriuretic peptide receptor tethers AHNAK1 at the plasma membrane to potentiate arachidonic acid-induced calcium mobilization]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1167</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1157</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1168?rss=1">
<title><![CDATA[T-cadherin is located in the nucleus and centrosomes in endothelial cells]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1168?rss=1</link>
<description><![CDATA[
<p>T-cadherin (H-cadherin, cadherin 13) is upregulated in vascular proliferative disorders and in tumor-associated neovascularization and is deregulated in many cancers. Unlike canonical cadherins, it lacks transmembrane and intracellular domains and is attached to the plasma membrane via a glycosylphosphatidylinositol anchor. T-cadherin is thought to function in signaling rather than as an adhesion molecule. Some interactive partners of T-cadherin at the plasma membrane have recently been identified. We examined T-cadherin location in human endothelial cells using confocal microscopy and subcellular fractionation. We found that a considerable proportion of T-cadherin is located in the nucleus and in the centrosomes. T-cadherin colocalized with a centrosomal marker -tubulin uniformly throughout the cell cycle at least in human umbilical vein endothelial cells. In the telophase, T-cadherin transiently concentrated in the midbody and was apparently degraded. Its overexpression resulted in an increase in the number of multinuclear cells, whereas its downregulation by small interfering RNA led to an increase in the number of cells with multiple centrosomes. These findings indicate that deregulation of T-cadherin in endothelial cells may lead to disturbances in cytokinesis or centrosomal replication.</p>
]]></description>
<dc:creator><![CDATA[Andreeva, A. V., Kutuzov, M. A., Tkachuk, V. A., Voyno-Yasenetskaya, T. A.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00237.2009</dc:identifier>
<dc:title><![CDATA[T-cadherin is located in the nucleus and centrosomes in endothelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1177</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1168</prism:startingPage>
<prism:section>VASCULAR BIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1178?rss=1">
<title><![CDATA[Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1178?rss=1</link>
<description><![CDATA[
<p>Recent studies suggest that the rapid and nongenomic effects of estradiol may be mediated through the G protein-coupled receptor dubbed GPR30 receptor. The present study examines the role of GPR30 versus a classical estrogen receptor (ER) in mediating the growth regulatory effects of estradiol. GPR30 is readily detectable in freshly isolated vascular tissue but barely detectable in cultured vascular smooth muscle cells (VSMC). In freshly isolated aortic tissue, estradiol stimulated extracellular signal-regulated kinases (ERK) phosphorylation. In contrast, in cultured VSMC, where GPR30 expression is significantly reduced, estradiol inhibits ERK phosphorylation. Transfer of the genes encoding GPR30 led to estradiol stimulation of ERK phosphorylation, which is opposite the effects of estradiol in the primary culture of VSMCs. Transduction of the mineralocorticoid receptor (MR) had no effect on estradiol effects on ERK. Estradiol-mediated stimulation of ERK subsequent to heterologous GPR30 expression was pertussis toxin sensitive and phosphoinositide 3-kinase (PI3 kinase) dependent; under these conditions, estradiol also inhibited protein kinase A (PKA). In contrast, in the absence of GPR30 expression in cultured VSMC, estradiol stimulated PKA activity and inhibited ERK phosphorylation. To determine the functional effect of GPR30 (vs. estrogen receptor expression), we assessed estradiol-mediated apoptosis. In the absence of GPR30 expression, estradiol inhibited apoptosis. This effect was enhanced with ER expression. In contrast, with GPR30 expression, estradiol stimulated apoptosis in an ERK-dependent manner. Thus the effect of estradiol on vascular smooth muscle cell apoptosis is likely dependent on the balance between ER-mediated PKA activation and GPR30-mediated PKA inhibition and PI3 kinase activation. Taken together, we postulate that modulation of GPR30 expression or activity may be an important determinant of the effects of estradiol in the vasculature.</p>
]]></description>
<dc:creator><![CDATA[Ding, Q., Gros, R., Limbird, L. E., Chorazyczewski, J., Feldman, R. D.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00185.2009</dc:identifier>
<dc:title><![CDATA[Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1187</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1178</prism:startingPage>
<prism:section>GROWTH, DIFFERENTIATION, AND APOPTOSIS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1188?rss=1">
<title><![CDATA[Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1188?rss=1</link>
<description><![CDATA[
<p>Phosphorylated Akt (p-Akt), a phosphoinositide-3-OH-kinase-activated protein kinase, is highly expressed in prostate tumors. p-Akt can indirectly hinder p53-dependent growth suppression and apoptosis by phosphorylating Mdm2. Alternatively, p-Akt can directly phosphorylate p21 and restrict it to the cytoplasm for degradation. Because the prostate is the highest zinc-accumulating tissue before the onset of cancer, the effects of physiological levels of zinc on Akt-Mdm2-p53 and Akt-p21 signaling axes in human normal prostate epithelial cells (PrEC) and malignant prostate LNCaP cells were examined in the present study. Cells were cultured for 6 days in low-zinc growth medium supplemented with 0 [zinc-deficient (ZD)], 4 [zinc-normal (ZN)], 16 [zinc-adequate (ZA)], or 32 [zinc-supplemented (ZS)] &micro;M zinc. Zinc status of both cell types was altered in a dose-dependent manner, with LNCaP cells reaching a plateau at &gt;16 &micro;M zinc. For both cell types, p-Akt was higher in the ZD than in the ZN cells and was normalized to that of the ZN cells by treatment with a PI3K inhibitor, LY-294002. PTEN, an endogenous phosphatase targeting Akt dephosphorylation, was hyperphosphorylated (p-PTEN, inactive form) in ZD PrEC. Nuclear p-Mdm2 was raised, whereas nuclear p53 was depressed, by zinc deficiency in PrEC. Nuclear p21 and p53 were lowered by zinc deficiency in LNCaP cells. Higher percentages of ZD, ZA, and ZS than ZN LNCaP cells were found at the G<SUB>0</SUB>/G<SUB>1</SUB> phase of the cell cycle, with proportionally lower precentages at the S and G<SUB>2</SUB>/M phases. Hence, the increased p-PTEN in ZD PrEC would result in hyperphosphorylation of p-Akt and p-Mdm2, as well as reduction of nuclear p53 accumulation. For ZD LNCaP cells, Akt hyperphosphorylation was probably mediated through p21 phosphorylation and degradation, thus restricting p21 nuclear entry to induce cell cycle arrest. Thus zinc deficiency differentially modulated the Akt-Mdm2-p53 signaling axis in normal prostate cells vs. the Akt-p21 signaling axis in malignant prostate cells.</p>
]]></description>
<dc:creator><![CDATA[Han, C.-T., Schoene, N. W., Lei, K. Y.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00042.2009</dc:identifier>
<dc:title><![CDATA[Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1199</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1188</prism:startingPage>
<prism:section>CELLULAR AND MITOCHONDRIAL METABOLISM</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1200?rss=1">
<title><![CDATA[Molecular regulation of cigarette smoke induced-oxidative stress in human retinal pigment epithelial cells: implications for age-related macular degeneration]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1200?rss=1</link>
<description><![CDATA[
<p>Cigarette smoke is the most important environmental risk factor for developing age-related macular degeneration (AMD). Damage to the retinal pigment epithelium (RPE) caused by cigarette smoke may underlie the etiology of AMD. This study investigated the molecular and cellular effects of cigarette smoke exposure on human RPE cells. ARPE-19 or primary human RPE cells were exposed to cigarette smoke extract (CSE) or hydroquinone (HQ), a component of cigarette smoke. The effect of this exposure on key aspects of RPE vitality including viability, cell size, mitochondrial membrane potential (<SUB>m</SUB>), superoxide production, 4-hydroxy-2-nonenal (4-HNE), vascular endothelial growth factor (VEGF), and heme oxygenase-1 (HO-1) expression was determined. Exposure of RPE cells to CSE or HQ caused oxidative damage and apoptosis, characterized by a reduction in cell size and nuclear condensation. Evidence of oxidative damage also included increased lipid peroxidation (4-HNE) and mitochondrial superoxide production, as well as a decrease in intracellular glutathione (GSH). Exogenous administration of antioxidants (GSH and <I>N</I>-acetyl-cysteine) prevented oxidative damage to the RPE cells caused by CSE. Cigarette smoke also induced expression of VEGF, HO-1, and the transcription factor nuclear factor erythroid-derived 2, like 2 (NRF2). However, NRF2 was only modestly involved in CSE-induced HO-1 expression, as shown by the NRF2 small interfering RNA studies. These new findings demonstrate that cigarette smoke is a potent inducer of oxidative damage and cell death in human RPE cells. These data support the hypothesis that cigarette smoke contributes to AMD pathogenesis by causing oxidative damage and cell death to RPE cells.</p>
]]></description>
<dc:creator><![CDATA[Bertram, K. M., Baglole, C. J., Phipps, R. P., Libby, R. T.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00126.2009</dc:identifier>
<dc:title><![CDATA[Molecular regulation of cigarette smoke induced-oxidative stress in human retinal pigment epithelial cells: implications for age-related macular degeneration]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1210</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1200</prism:startingPage>
<prism:section>NERVOUS SYSTEM CELL BIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1211?rss=1">
<title><![CDATA[The mechanical behavior of individual sarcomeres of myofibrils isolated from rabbit psoas muscle]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1211?rss=1</link>
<description><![CDATA[
<p>The goal of this study was to develop a system to experiment with sarcomeres mechanically isolated from skeletal muscles. Single myofibrils from rabbit psoas were transferred into a temperature-controlled (22&deg;C or 15&deg;C) experimental chamber, and sarcomeres were isolated using precalibrated glass microneedles that were pierced externally, adjacent to the Z-lines. The force produced during activation was measured by tracking the displacement of the microneedles, and the sarcomere and half-sarcomere changes were measured by continuously tracking the Z-lines and A-bands position during the experiments. Sarcomeres produced a stress (force/cross-sectional area) of 112.75 &plusmn; 4.96 nN/&micro;m<sup>2</sup> (15&deg;C) and 128.47 &plusmn; 5.58 nN/&micro;m<sup>2</sup> (22&deg;C) at lengths between 2.0 &micro;m and 2.4 &micro;m. The descending limb was fitted with linear regression for length between 2.4 &micro;m and 3.5 &micro;m, which provided an abscissa extrapolating to 3.87 &micro;m. The force-length relation was remarkably similar to a theoretical curve based on the degree of filament overlap. During sarcomere activation, we tracked the distance between the center of the A-band and the Z-lines. At lengths below 1.6 &micro;m, movements of A-band were not detected. A-band movements increased with length to achieve a maximum displacement of 59.40 &plusmn; 10.1 nm from the center at 2.0 &micro;m&ndash;2.4 &micro;m. A-band displacement decreased linearly in sarcomere lengths between 2.6 &micro;m and 3.6 &micro;m. A technique for monitoring force and length in single sarcomeres isolated from myofibrils represents a reliable technique to evaluate contractile mechanisms at the most basic, intact level of muscle organization, opening the possibility to clarify long-standing issues in the field of muscle contraction.</p>
]]></description>
<dc:creator><![CDATA[Pavlov, I., Novinger, R., Rassier, D. E.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00233.2009</dc:identifier>
<dc:title><![CDATA[The mechanical behavior of individual sarcomeres of myofibrils isolated from rabbit psoas muscle]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1219</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1211</prism:startingPage>
<prism:section>METHODS IN CELL PHYSIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1220?rss=1">
<title><![CDATA[Hepatocyte nuclear factor 1 is essential for transcription of sodium-dependent vitamin C transporter protein 1]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1220?rss=1</link>
<description><![CDATA[
<p>Transport and distribution of vitamin C is primarily regulated by the function of sodium-dependent vitamin C transporters (SVCTs). SVCT1 is expressed in the small intestine, liver, and kidney, organs that play a vital role in whole body vitamin C homeostasis. Despite the importance of this protein, little is known about regulation of the gene encoding SVCT1, <I>Slc23a1</I>. In this study, we present the first investigation of the transcriptional regulation of human <I>Slc23a1</I>, identifying transcription factors that may influence its expression. A 1,239-bp genomic DNA fragment corresponding to the 5'-flanking region of <I>Slc23a1</I> was isolated from a human hepatocarcinoma cell line (HepG2) and sequenced. When cloned into a reporter gene construct, robust transcriptional activity was seen in this sequence, nearly 25-fold above the control vector. Deletion analysis of the SVCT1 reporter gene vector defined the minimal active promoter as a small 135-bp region upstream of the transcriptional start site. While several transcription factor binding sites were identified within this sequence, reporter constructs showed that basal transcription required the binding of hepatic nuclear factor 1 (HNF-1) to its cognate sequence. Furthermore, mutation of this HNF-1 binding site resulted in complete loss of luciferase expression, even in the context of the whole promoter. Additionally, small interfering RNA knockdown of both members of the HNF-1 family, HNF-1 and HNF-1&beta;, resulted in a significant decline in SVCT1 transcription. Together, these data suggest that HNF-1 and/or HNF-1&beta; binding is required for SVCT1 expression and may be involved in the coordinate regulation of whole body vitamin C status.</p>
]]></description>
<dc:creator><![CDATA[Michels, A. J., Hagen, T. M.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00348.2009</dc:identifier>
<dc:title><![CDATA[Hepatocyte nuclear factor 1 is essential for transcription of sodium-dependent vitamin C transporter protein 1]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1227</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1220</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1228?rss=1">
<title><![CDATA[IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1228?rss=1</link>
<description><![CDATA[
<p>Changes in placental nutrient transport are closely associated with abnormal fetal growth. However, the molecular mechanisms underlying the regulation of placental amino acid transporters are unknown. We demonstrate that physiological concentrations of the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)- stimulate the activity of amino acid transporter system A, but not system L, in cultured human primary trophoblast cells. Both cytokines increased the gene and protein expression of the Na<sup>+</sup>-coupled neutral amino acid transporter (SNAT)2 isoform and upregulated SNAT1 protein expression. IL-6 increased Tyr705 phosphorylation of signal transducer and activator of transcription 3 (STAT3). In cells transfected with small interfering RNA (siRNA) targeting STAT3, the RNA and protein expression of SNAT2, but not SNAT1, was reduced and the stimulating effect of IL-6 on system A activity was abolished. Despite eliciting similar responses in amino acid transport activity and transporter expression, TNF- effects on system A activity were not mediated through the JAK/STAT pathway. In conclusion, we have identified a novel regulatory pathway involving increased gene expression of the SNAT2 isoform mediated by a STAT-dependent pathway, which links IL-6 to increased activity of system A, a ubiquitously expressed transporter of neutral amino acids. From these new findings, we propose that upregulation of amino acid transporters by cytokines may contribute to increased placental nutrient transport and fetal overgrowth, which are commonly found in pregnancies complicated by maternal diabetes and obesity.</p>
]]></description>
<dc:creator><![CDATA[Jones, H. N., Jansson, T., Powell, T. L.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00195.2009</dc:identifier>
<dc:title><![CDATA[IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1235</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1228</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1236?rss=1">
<title><![CDATA[Closed-state inactivation in Kv4.3 isoforms is differentially modulated by protein kinase C]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1236?rss=1</link>
<description><![CDATA[
<p>Kv4.3, with its complex open- and closed-state inactivation (CSI) characteristics, is a primary contributor to early cardiac repolarization. The two alternatively spliced forms, Kv4.3-short (Kv4.3-S) and Kv4.3-long (Kv4.3-L), differ by the presence of a 19-amino acid insert downstream from the sixth transmembrane segment. The isoforms are similar kinetically; however, the longer form has a unique PKC phosphorylation site. To test the possibility that inactivation is differentially regulated by phosphorylation, we expressed the Kv4.3 isoforms in <I>Xenopus</I> oocytes and examined changes in their inactivation properties after stimulation of PKC activity. Whereas there was no difference in open-state inactivation, there were profound differences in CSI. In Kv4.3-S, PMA reduced the magnitude of CSI by 24% after 14.4 s at &ndash;50 mV. In contrast, the magnitude of CSI in Kv4.3-L increased by 25% under the same conditions. Mutation of a putatively phosphorylated threonine (T504) to aspartic acid within a PKC consensus recognition sequence unique to Kv4.3-L eliminated the PMA response. The change in CSI was independent of the intervention used to increase PKC activity; identical results were obtained with either PMA or injected purified PKC. Our previously published 11-state model closely simulated our experimental data. Our data demonstrate isoform-specific regulation of CSI by PKC in Kv4.3 and show that the carboxy terminus of Kv4.3 plays an important role in regulation of CSI.</p>
]]></description>
<dc:creator><![CDATA[Xie, C., Bondarenko, V. E., Morales, M. J., Strauss, H. C.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00144.2009</dc:identifier>
<dc:title><![CDATA[Closed-state inactivation in Kv4.3 isoforms is differentially modulated by protein kinase C]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1248</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1236</prism:startingPage>
<prism:section>MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1249?rss=1">
<title><![CDATA[17{beta}-Estradiol regulates the first steps of skeletal muscle cell differentiation via ER-{alpha}-mediated signals]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1249?rss=1</link>
<description><![CDATA[
<p>17&beta;-Estradiol (E<SUB>2</SUB>) mediates a wide variety of complex biological processes determining the growth and development of reproductive tract as well as nonreproductive tissues of male and female individuals. While E<SUB>2</SUB> effects on the reproductive system, bone, and cardiovascular system are quite well established, less is known about how it affects the physiology of other tissues. Skeletal muscle is a tissue that is expected to be E<SUB>2</SUB> responsive since both isoforms of estrogen receptor (ER- and ER-&beta;) are expressed. Significant sex-related differences have been described in skeletal muscle, although the role played by E<SUB>2</SUB> and the mechanisms underlying it remain to be determined. Here, we demonstrate that E<SUB>2</SUB> increases the glucose transporter type 4 translocation at membranes as well as the expression of well-known differentiation markers of myogenesis (i.e., myogenin and myosin heavy chain) in rat myoblast cells (L6). These E<SUB>2</SUB>-induced effects require rapid extranuclear signals and the presence of ER-, whereas no contribution of IGF-I receptor has been observed. In particular, ER--dependent Akt activation participates in regulating the first step of myogenic differentiation. Moreover, both receptors mediate the E<SUB>2</SUB>-induced activation of p38, which, in turn, affects the expression of myogenin and myosin heavy chain. All together, these data indicate that E<SUB>2</SUB> should be included in the list of skeletal muscle trophic factors.</p>
]]></description>
<dc:creator><![CDATA[Galluzzo, P., Rastelli, C., Bulzomi, P., Acconcia, F., Pallottini, V., Marino, M.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00188.2009</dc:identifier>
<dc:title><![CDATA[17{beta}-Estradiol regulates the first steps of skeletal muscle cell differentiation via ER-{alpha}-mediated signals]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1262</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1249</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1263?rss=1">
<title><![CDATA[Transforming growth factor-{beta}1 downregulates caveolin-1 expression and enhances sphingosine 1-phosphate signaling in cultured vascular endothelial cells]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1263?rss=1</link>
<description><![CDATA[
<p>In vascular endothelial cells, specialized microdomains of plasma membrane termed caveolae modulate various receptor signal transduction pathways regulated by caveolin-1, a resident protein of caveolae. We examined whether transforming growth factor-&beta;1 (TGF-&beta;1), a multifunctional cytokine, alters expression levels of caveolin-1 and influences heterologous receptor signaling. Treatment of cultured bovine aortic endothelial cells (BAEC) with TGF-&beta;1 induces marked decreases in caveolin-1 expression in a time- and dose-dependent fashion at both levels of protein and mRNA. A pharmacological inhibitor of activin receptor-like kinase 5 (ALK-5) counteracts caveolin-1 downregulation by TGF-&beta;1, indicating the involvement of ALK-5 receptor subtype for TGF-&beta;1. Sphingosine 1-phosphate (S1P) is a serum-borne angiogenic lipid growth factor that exerts a wide variety of biological actions. S1P modulates G protein-coupled S1P receptors, activating downstream molecules kinases AMP-activated protein kinase (AMPK), and Akt as well as a small G protein Rac1, ultimately to promote migration. Because S1P receptor signaling is associated with caveolae/caveolin-1, we examined whether pretreatment with TGF-&beta;1 enhances effects of S1P on BAEC. Whereas S1P alone evokes robust BAEC responses to S1P, pretreatment with TGF-&beta;1 leads to even higher magnitudes of S1P-elicited signaling responses and cell migration. Conversely, genetic knockdown of caveolin-1 using small interfering RNA mimics TGF-&beta;1-induced promotion of BAEC responses to S1P. Collectively, these data demonstrate that TGF-&beta;1 downregulates caveolin-1 of cultured endothelial cells, involving ALK-5 receptor subtype. Because downregulation of caveolin-1 by TGF-&beta;1 promotes subsequent heterologous receptor signaling by S1P, these results may also identify novel point of cross-talk between cytokines and sphingolipids within endothelial signal transduction machineries.</p>
]]></description>
<dc:creator><![CDATA[Igarashi, J., Shoji, K., Hashimoto, T., Moriue, T., Yoneda, K., Takamura, T., Yamashita, T., Kubota, Y., Kosaka, H.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00109.2009</dc:identifier>
<dc:title><![CDATA[Transforming growth factor-{beta}1 downregulates caveolin-1 expression and enhances sphingosine 1-phosphate signaling in cultured vascular endothelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1274</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1263</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1275?rss=1">
<title><![CDATA[Mind bomb 1 regulation of cFLIP interactions]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1275?rss=1</link>
<description><![CDATA[
<p>Mind bomb 1 (Mib1) is a multidomain E3 ligase that directs ubiquitination of the Notch ligands Delta and Jagged to promote their endocytosis. Here we examine Notch-independent functions of Mib1 and find that its activities are linked to the initiation of the extrinsic cell death pathway. Expression of Mib1 induces a spontaneous, caspase-dependent cell death. Consistent with this, depletion of endogenous Mib1 decreases tumor-necrosis factor (TNF)-induced cell death. Mib1 was found to bind to cellular Fas-associated death domain (FADD)-like IL-1b converting enzyme (FLICE)-like inhibitory proteins (cFLIP-L and cFLIP-S), whereas only cFLIP-s can inhibit Mib1-induced cell death. The interaction between Mib1 and cFLIP decreases the association of caspase-8 with cFLIP, which activates caspase-8 and induces cell death. Collectively, these results suggest that in addition to a central role in Notch signaling, Mib1 has an important role in regulating the extrinsic cell death pathway.</p>
]]></description>
<dc:creator><![CDATA[Zhang, L., Gallagher, P. J.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00214.2009</dc:identifier>
<dc:title><![CDATA[Mind bomb 1 regulation of cFLIP interactions]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1283</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1275</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1284?rss=1">
<title><![CDATA[MEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1284?rss=1</link>
<description><![CDATA[
<p>Human bone marrow mesenchymal stem cells (MSCs) are a potent source of growth factors, which are partly responsible for their beneficial paracrine effects. We reported previously that transforming growth factor- (TGF-), a putative mediator of wound healing and the injury response, increases the release of vascular endothelial growth factor (VEGF), augments tumor necrosis factor- (TNF-)-stimulated VEGF production, and activates mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI-3K) pathway in human MSCs. The experiments described in this report indicate that TGF- increases MSC-derived hepatocyte growth factor (HGF) production. TGF--stimulated HGF production was abolished by inhibition of MEK, p38, PI-3K, or by small interfering RNA (siRNA) targeting TNF receptor 2 (TNFR2), but was not attenuated by siRNA targeting TNF receptor 1 (TNFR1). Ablation of TNFR1 significantly increased basal and stimulated HGF. A potent synergy between TGF- and TNF- was noted in MSC HGF production. This synergistic effect was abolished by MEK, P38, PI-3K inhibition, or by ablation of both TNF receptors using siRNA. We conclude that <I>1</I>) novel cross talk occurs between tumor necrosis factor receptor and TGF-/epidermal growth factor receptor in stimulating MSC HGF production; <I>2</I>) this cross talk is mediated, at least partially, via activation of MEK, p38, and PI-3K; <I>3</I>) TGF- stimulates MSCs to produce HGF by MEK, p38, PI-3K, and TNFR2-dependent mechanisms; and <I>4</I>) TNFR1 acts to decrease basal TGF- and TNF--stimulated HGF.</p>
]]></description>
<dc:creator><![CDATA[Wang, Y., Weil, B. R., Herrmann, J. L., Abarbanell, A. M., Tan, J., Markel, T. A., Kelly, M. L., Meldrum, D. R.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00183.2009</dc:identifier>
<dc:title><![CDATA[MEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1293</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1284</prism:startingPage>
<prism:section>RECEPTORS AND SIGNAL TRANSDUCTION</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1294?rss=1">
<title><![CDATA[Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1294?rss=1</link>
<description><![CDATA[
<p>The cholinergic anti-inflammatory pathway is a physiological mechanism that inhibits cytokine production and minimizes tissue injury during inflammation. Previous investigations revealed that cholinergic stimulation (via cholinergic agonists and vagus nerve stimulation) suppresses endothelial cell activation and leukocyte recruitment. The purpose of this study was to investigate the mechanisms by which cholinergic agonists (e.g., nicotine and GTS-21) regulate endothelial cell activation. Specifically, we examined the effects of cholinergic agonists on IL-6-mediated endothelial cell activation through the JAK2/STAT3 signaling pathway. Treatment of macrovascular human umbilical vein endothelial cells (HUVECs) and microvascular endothelial cells (MVECs) with the cholinergic agonists nicotine and GTS-21 significantly reduced IL-6-mediated monocyte chemoattractant protein-1 (MCP-1) production and ICAM-1 expression which are regulated through the JAK2/STAT3 pathway. We found that treatment of endothelial cells with cholinergic agonists significantly reduced STAT3 activation by phosphorylation and DNA binding. The inhibition of STAT3 phosphorylation was reversed by sodium orthovanadate, an inhibitor of tyrosine phosphatases, as well as by NSC-87877 suggesting a SHP1/2-dependent mechanism. Further investigations showed that cholinergic agonists reduced the phosphorylation of JAK2, an upstream component of the JAK2/STAT3 pathway. Finally, we observed that nicotine and GTS-21 treatment decreased levels of SOCS3 (suppressor of cytokine signaling; a regulator of the inflammatory activity of IL-6) in activated endothelial cells. These data demonstrate that cholinergic agonists suppress IL-6-mediated endothelial cell activation through the JAK2/STAT3 pathway. Our results have significant implications for better understanding the therapeutic potential of cholinergic agonists for treating IL-6 mediated inflammatory conditions.</p>
]]></description>
<dc:creator><![CDATA[Chatterjee, P. K., Al-Abed, Y., Sherry, B., Metz, C. N.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00160.2009</dc:identifier>
<dc:title><![CDATA[Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1306</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1294</prism:startingPage>
<prism:section>VASCULAR BIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1307?rss=1">
<title><![CDATA[Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1307?rss=1</link>
<description><![CDATA[
<p>Individuals with Type 2 diabetes mellitus (T2DM) are at increased risk of saphenous vein (SV) graft stenosis following coronary artery bypass. Graft stenosis is caused by intimal hyperplasia, a pathology characterized by smooth muscle cell (SMC) proliferation and migration. We hypothesized that SV-SMC from T2DM patients were intrinsically more proliferative and migratory than those from nondiabetic individuals. SV-SMC were cultured from nondiabetic and T2DM patients. Cell morphology (light microscopy, immunocytochemistry), S100A4 expression (real-time RT-PCR, immunoblotting), proliferation (cell counting), migration (Boyden chamber assay), and cell signaling (immunoblotting with phosphorylation state-specific antibodies) were studied. SV-SMC from T2DM patients were morphologically distinct from nondiabetic patients and exhibited a predominantly rhomboid phenotype, accompanied by disrupted F-actin cytoskeleton, disorganized -smooth muscle actin network, and increased focal adhesion formation. However, no differences were observed in expression of the calcium-binding protein S100A4, a marker of rhomboid SMC phenotype, between the two cell populations. T2DM cells were less proliferative in response to fetal calf serum than nondiabetic cells, but both populations had similar proliferative responses to insulin plus PDGF. Under high glucose concentration conditions in the presence of insulin, migration of diabetic SV-SMC was greater than nondiabetic cells. Glucose concentration did not affect SV-SMC proliferation. No differences in insulin or PDGF-induced phosphorylation of ERK-1/2 or components of the Akt pathway (Akt-Ser473, Akt-Thr308, and GSK-3&beta;) were apparent between the two populations. In conclusion, SV-SMC from T2DM patients differ from nondiabetic SV-SMC in that they exhibit a rhomboid phenotype and are more migratory, but less proliferative, in response to serum.</p>
]]></description>
<dc:creator><![CDATA[Madi, H. A., Riches, K., Warburton, P., O'Regan, D. J., Turner, N. A., Porter, K. E.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00608.2008</dc:identifier>
<dc:title><![CDATA[Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1317</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1307</prism:startingPage>
<prism:section>VASCULAR BIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1318?rss=1">
<title><![CDATA[Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor {alpha}-converting enzyme]]></title>
<link>http://ajpcell.physiology.org/cgi/content/abstract/297/5/C1318?rss=1</link>
<description><![CDATA[
<p>Angiotensin-converting enzyme 2 (ACE2) is a newly identified regulator of the renin-angiotensin system. This type I membrane-anchored protein has a catalytically active ectodomain that undergoes shedding. Tumor necrosis factor -converting enzyme (TACE) has been shown to be involved in ACE2 shedding. Although pathophysiological significance of ACE2 shedding has been suggested, regulation of this process by TACE is not clearly defined. We characterized TACE-mediated constitutive ectodomain shedding of ACE2 using wild-type Chinese Hamster Ovary (WT-CHO), the TACE-mutant M2 (M2-CHO) cells, and EC-4 and EC-2 cells that are fibroblasts from wild-type and TACE-null mice, respectively. ACE2 was constitutively cleaved to release two distinct major soluble forms. The deglycosylated molecular masses of the larger (LSF) and smaller soluble form (SSF) were ~80 and 70 kDa, respectively. These forms had equivalent enzyme activities. Reduced shedding for the LSF from M2-CHO and EC-2 cells when compared with WT-CHO and EC-4 cells, respectively, was noted. TACE reconstitution in EC-2 cells expressing ACE2 resulted in increase in LSF but not SSF release, demonstrating a main role of TACE in LSF release and distinct regulations of release of the two soluble forms. Deletions of the juxtamembrane region of ACE2 reduced LSF release in CHO cell lines, whereas it abolished TACE-induced shedding in EC-2 cells. Analysis of TACE structural domains confirmed that the active site in the catalytic domain is essential for ACE2 shedding but that noncatalytic domains also play additional roles. These results demonstrate selective and specific regulation of constitutive shedding of ACE2 by TACE.</p>
]]></description>
<dc:creator><![CDATA[Iwata, M., Silva Enciso, J. E., Greenberg, B. H.]]></dc:creator>
<dc:date>Wed, 28 Oct 2009 17:34:45 PDT</dc:date>
<dc:identifier>info:doi/10.1152/ajpcell.00036.2009</dc:identifier>
<dc:title><![CDATA[Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor {alpha}-converting enzyme]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>5</prism:number>
<prism:volume>297</prism:volume>
<prism:endingPage>C1329</prism:endingPage>
<prism:publicationDate>2009-11-01</prism:publicationDate>
<prism:startingPage>C1318</prism:startingPage>
<prism:section>CELLULAR AND MITOCHONDRIAL METABOLISM</prism:section>
</item>

</rdf:RDF>